Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
VistaGen Therapeutics Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 24 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.39|
|52-week range||$0.61 - $3.55|
|50-day moving average||$2.83|
|200-day moving average||$2.67|
|Wall St. target price||$7.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.39|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||-3.24%|
|1 month (2021-09-17)||-19.80%|
|3 months (2021-07-16)||-12.77%|
|6 months (2021-04-16)||16.59%|
|1 year (2020-10-16)||192.86%|
|2 years (2019-10-17)||102.54%|
|3 years (2018-10-17)||20.10%|
|5 years (2016-10-17)||4.1899|
|Revenue TTM||$1.4 million|
|Gross profit TTM||$1.1 million|
|Return on assets TTM||-25.62%|
|Return on equity TTM||-49.03%|
|Market capitalisation||$461 million|
TTM: trailing 12 months
There are currently 12.1 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 29.5% up from 9.3 million last month.
There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.
VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 1.2 million). VistaGen Therapeutics's SIR currently stands at 10.16. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 10160 shares are currently held short.
However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0866% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 87 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against VistaGen Therapeutics.
Find out more about how you can short VistaGen Therapeutics stock.
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.
VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.6088 up to $3.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.9989. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).
VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd. ; license and option agreements with Pherin Pharmaceuticals, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.